Det siger de hos Jim
-
Eli Lilly's next-generation weight-loss injectable retatrutide helped obesity patients lose 28% of their body weight on average in a late-stage trial. This more powerful drug may not be for everybody, but it helps Lilly build out a broader GLP-1 portfolio alongside injectable Zepbound and pill Foundayo. It's about options. Clear leader over Novo Nordisk.
Mon det passer at Novo er "second"
-
Det handler mindre om procenter, men derimod om bivirkninger, der kan forhindre brugere i at benytte et produkt over en længere periode...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind